

Dissociation Constants of Ethane-1-hydroxy-1,1-diphosphonate [EHDP] and Dichloromethylene-diphosphonate [Cl₂MDP] for H⁺, Ca²⁺, Mg²⁺ and Zn²⁺

Peter Dietsch, Theodor Günther, and Manfred Röhnehl

Institut für Biochemie und Molekularbiologie und Anatomisches Institut, Freie Universität Berlin

(Z. Naturforsch. 31 c, 661—663 [1976]; received August 23/September 17, 1976)

Diphosphonates, Dissociation Constants

The dissociation constants of ethane-1-hydroxy-1,1-diphosphonate [EHDP] and dichloromethylene-diphosphonate [Cl₂MDP] for H⁺, Ca²⁺, Mg²⁺ and Zn²⁺ have been determined from pH-titration curves. EHDP forms more stable chelates with Ca²⁺, Mg²⁺ and Zn²⁺ than Cl₂MDP. Cl₂MDP is a stronger acid than EHDP.

Introduction

The diphosphonates EHDP and Cl₂MDP have been used for studying bone metabolism and for treatment of bone diseases¹⁻⁴. Both substances are adsorbed to apatite, EHDP being more strongly bound than Cl₂MDP^{5,6}. EHDP preferentially inhibits the growth of apatite crystals and mineralization, Cl₂MDP, however, especially inhibits resorption of bone⁷. As yet, there has been no explanation for this fundamental difference in the action of EHDP and Cl₂MDP.

For the interpretation of additional effects, it was suggested that EHDP chelates divalent cations and thus inhibits Ca²⁺-dependent enzymes involved in the formation of collagen fibrils and Zn²⁺-dependent pyrophosphatase⁸.

For characterizing these effects of EHDP and Cl₂MDP quantitatively, we determined their dissociation constants for H⁺, Ca²⁺, Mg²⁺, and Zn²⁺.

Methods

pH titrations were performed at 25 °C with 10 ml of 1 mM solutions of EHDP and Cl₂MDP * in 0.1 M KCl by adding 10 µl portions of 0.1 N KOH and gassing with purified N₂. 10 mM CaCl₂, MgCl₂ or ZnCl₂ was added. The procedure was extensively described by Dietsch and Siegmund⁹.

Abbreviations: EHDP, ethane-1-hydroxy-1,1-diphosphonate; Cl₂MDP, dichloromethylene-diphosphonate.

Requests for reprints should be sent to Professor Dr. T. Günther, Institut für Biochemie und Molekularbiologie der FU Berlin, Arnimallee 22, D-1000 Berlin 33.

* EHDP and Cl₂MDP were gifts of Firma Henkel and Co, GmbH, Düsseldorf, Germany.

According to Schwarzenbach¹⁰, titration curves of weak acids are given by the equation

$$\sum_{j=0}^n (g-j) \cdot [H^+]^j \cdot K_{HjZ}^H = 0.$$

The symbols were used as defined by Schwarzenbach¹⁰. *n*, number of individual equilibrium constants; *j*, indicates which proton dissociates; *m*, number of dissociable protons; *a*, mol of KOH added per mol of ligand; *g*, real degree of protonation; K_{H₂Z}^H, K_{H₃Z}^H dissociation constants for the third and fourth H⁺ ion, respectively

$$e. g. K_{H_2Z}^H = \frac{[H^+] \cdot [EHDP^{4-}]}{[HEHDP^{3-}]};$$

pK_a, negative logarithm of acid dissociation constant; pK_a', apparent pK_a in the presence of a divalent cation; K_{ZM}^M, K_{H₂ZM}^M formation constants for the single protonated and nonprotonated complexes

$$e. g. K_{H_2ZM}^H = \frac{[HEHDP^{3-}] [M^{2+}]}{[MH_2EHDP^{-}]};$$

pM, negative logarithm of divalent cation concentration.

By restriction to the dissociation constants K_{H₂Z}^H and K_{H₃Z}^H, which correspond to the dissociation of the last two protons involved in complex formation one gets

$$g \cdot \frac{1}{K_{H_2Z}^H} + (g-2) \cdot [H^+]^2 \cdot K_{H_3Z}^H = -(g-1) \cdot [H^+]. \quad (1)$$

g was determined according to Eqn (2)

$$g = m - a + \frac{[OH^-] - [H^+]}{[Z]} \quad (2)$$

and was substituted into Eqn (1) to obtain K_{H₂Z}^H and K_{H₃Z}^H.

The association constants of the metal chelates were calculated from Eqn (3)

$$\log K = pK_a + pK_a' + pM. \quad (3)$$

For detailed description of calculation and computer program see Dietsch and Siegmund⁹ and Dietsch¹¹.

Results

Tab. I contains the pK_a-values of EHDP and Cl₂MDP, Tab. II the logarithms of the complex binding constants determined from the pH titration

Tab. I. pK_a-values of EHDP and Cl₂MDP at 25 °C in 0.1 M KCl. The pK_{a1}-values of EHDP and Cl₂MDP are not detectable by this method, because they are strong acids. Mean ± S.E., *n* = 10.

	pK _{a1}	pK _{a2}	pK _{a3}	pK _{a4}
EHDP	<2	2.5 ± 0.2	6.89 ± 0.01	10.60 ± 0.02
Cl ₂ MDP	<2	2.3 ± 0.2	5.82 ± 0.01	8.84 ± 0.01

Tab. II. Logarithms of the stability constants of the chelates of EHDP and Cl₂MDP with Ca²⁺, Mg²⁺ and Zn²⁺ at 25° in 0.1 M KCl. Mean ± S.E. *n* = 10.

Me ²⁺	EHDP		Cl ₂ MDP	
	log K _{HZM} ^M	log K _{ZM} ^M	log K _{HZM} ^M	log K _{ZM} ^M
Ca	3.0	6.0	2.86 ± 0.01	4.71 ± 0.01
Mg	3.03 ± 0.02	6.17 ± 0.02	2.92 ± 0.01	4.75 ± 0.01
Zn	5.00 ± 0.04	8.19 ± 0.04	4.61 ± 0.01	6.70 ± 0.02

curves [not shown]. The titration curve of EHDP with Ca²⁺ was performed only in the presence of 5 mM Ca²⁺, because at higher Ca²⁺ concentrations and at higher pH values Ca[OH]₂ was formed. Because there was not a large excess of Ca²⁺, the Ca²⁺-ion concentration cannot be considered as being constant during the titration. Thus the values of the stability constants of CaEHDP [Tab. II] are probably not as precise as the other values and therefore S. E. was not given. The stability constants increase in the order Ca < Mg < Zn in agreement with the Irving-Williams series.

EHDP forms stronger complexes with Ca²⁺, Mg²⁺ and Zn²⁺ than Cl₂MDP or pyrophosphate. Probably the OH group from the hydroxyethyl group is involved in the chelate formation, resulting in a stronger chelate effect.

Cl₂MDP is a stronger acid than EHDP [Table I] or phosphoric acid. This property can be attributed to the inductive effect of the two chlorine atoms on the methylene group. A well known analogous

example is trichloroacetic acid which is a stronger acid than acetic acid.

Discussion

The physico-chemical constants may give an explanation for the different pharmacological behaviour of EHDP and Cl₂MDP. Since EHDP has a higher affinity for Ca²⁺ ions, EHDP could also be more strongly bound to Ca²⁺ ions at the growing points of the apatite crystal [active growth sites]. A similar mechanism has been proposed by Meyer and Nancollas¹². In the growth of apatite crystals, EHDP may compete with phosphate for the Ca²⁺ ions at the growing points of apatite crystals. [Phosphate has a lower affinity for Ca²⁺ than EHDP.] Thus EHDP inhibits mineralization more strongly than Cl₂MDP. At higher concentrations the Cl₂MDP can also compete successfully with the phosphate to inhibit mineralization.

In the resorption of bone the osteoclasts are involved. Rowe and Hausmann¹³ suggested that the inhibition of bone resorption by diphosphonates is due to abnormal osteoclasts, however, there was no sufficient quantitative correlation.

Therefore, we will propose another mechanism for the inhibition of bone resorption by Cl₂MDP based on the fact, that Cl₂MDP is a stronger acid than EHDP.

There is evidence, that the resorption of apatite and bone involves H⁺ ions, which are formed by carbonic anhydrase of the osteoclasts¹⁴⁻¹⁷. The weaker acid EHDP, adsorbed to apatite, is more easily protonated than the stronger acid Cl₂MDP by the local H⁺ ion activity at the apatite crystal near the surface of the osteoclasts. The protonated acids [EHDP, phosphoric acid] may be dissolved from the apatite crystal, whereas the stronger acid Cl₂MDP remains deprotonated and adsorbed to the apatite and, unlike EHDP, inhibits bone resorption.

As there is an equilibrium in the bone between adsorbed and dissolved EHDP or Cl₂MDP, the dissolved diphosphonate can bind some Mg²⁺, Ca²⁺ and Zn²⁺ in the extracellular fluid [ECF]. However, the concentration of dissolved diphosphonates in the ECF is low compared to the concentration of Ca²⁺ and Mg²⁺, therefore, a significant reduction of the Ca²⁺ and Mg²⁺ ion activity *in vivo* may be excluded. Since most of the Zn²⁺ is bound to proteins, the ion activity of Zn²⁺ is unknown, and it remains open, whether the Zn²⁺ activity is reduced *in vivo*.

- ¹ R. G. G. Russell and H. Fleisch, *Clin. Orthop.* **69**, 101–117 [1970].
- ² R. Smith, R. G. G. Russell, M. C. Bishop, C. G. Woods, and M. Bishop, *Quarterly J. Med.* **42**, 235–254 [1973].
- ³ D. A. Basset and F. Macagno, *Lancet* **2**, 845–846 [1968].
- ⁴ R. J. Cates, D. D. Sheets, and C. C. Johnston, *Clin. Res.* **19**, 437 [1971].
- ⁵ R. G. G. Russell and R. Smith, *J. Bone Jt. Surg. B* **55**, 66–68 [1973].
- ⁶ A. Jung, S. Bisaz, and H. Fleisch, *Calcif. Tiss. Res.* **11**, 269–280 [1973].
- ⁷ R. Schenk, W. A. Merz, R. Mühlbauer, R. G. G. Russell, and H. Fleisch, *Calcif. Tiss. Res.* **11**, 196–214 [1973].
- ⁸ A. Larsson, *Calcif. Tiss. Res.* **16**, 109–127 [1974].
- ⁹ P. Dietsch and P. Siegmund, *Z. Naturforsch.* **27b**, 509–513 [1972].
- ¹⁰ G. Schwarzenbach, *Helv. Chim. Acta* **33**, 947–962 [1950].
- ¹¹ P. Dietsch, Diss., Fachbereich Chemie, FU Berlin 1974.
- ¹² J. L. Meyer and G. H. Nancollas, *Calcif. Tiss. Res.* **13**, 295–303 [1973].
- ¹³ D. J. Rowe and E. Hausmann, *Calcif. Tiss. Res.* **20**, 53–60 [1976].
- ¹⁴ H. J. Dulce, P. Siegmund, F. Körber, and E. Schütte, *Hoppe-Seyler's Z. Physiol. Chem.* **320**, 163–167 [1960].
- ¹⁵ H. J. Dulce, *Calcium metabolism, bone and metabolic bone diseases* (F. Kuhlencordt and H.-P. Kruse, eds.), p. 197–210, Springer Verlag, Berlin, Heidelberg, New York 1975.
- ¹⁶ W. J. Mueller, R. L. Brubaker, C. V. Gay, and J. N. Boelkins, *Fed. Proc.* **32**, 1951–1954 [1973].
- ¹⁷ L. C. Waite, W. A. Volkert, and A. D. Kenny, *Endocrinology* **87**, 1129–1139 [1970].